Oncology has long been a bottleneck for AI trainers: patient privacy rules and small trial cohorts make real-world cancer data some of the priciest and most legally fraught in health care. If Nature is examining AI-generated synthetic data as a substitute, that's a signal to watch for pharma, hospitals, and data brokers who currently gatekeep this data — synthetic generation could either crater the price of oncology datasets or, if regulators demand provenance and validation, create a new certification market instead.
Either way, buyers like clinical AI startups and CROs will be watching how much trust regulators place in generated substitutes.
Artificial intelligence-generated synthetic data for cancer research and clinical trials
— Nature
